James Mangan, Associate Clinical Professor of Medicine
James K. Mangan, MD, PhD, is a board-certified hematologist who specializes in treating people with blood cancers, including acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. He also has expertise in treating people with myelodysplastic syndromes, myeloproliferative neoplasms, aplastic anemia, lymphoma, and myeloma.
Dr. Mangan performs allogeneic stem cell transplants, also known as allogeneic bone marrow transplants. This type of transplant uses stem cells from a related or matched donor to replace diseased bone marrow. He also performs autologous stem cell transplants, which use a patient's own stem cells.
An associate professor in the Department of Medicine, Dr. Mangan actively researches ways to improve treatment options and outcomes for people with blood diseases and disorders.
Prior to joining UC San Diego Health in 2019, he was an assistant professor at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Mangan completed fellowship training in hematology and oncology at the University of Pennsylvania Perelman School of Medicine and residency training in internal medicine at the University of Michigan Medical School. He earned a doctorate in molecular biology and medical degree from Temple University School of Medicine.
He is a member of the American Society of Hematology and American Society for Blood and Marrow Transplantation.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Kura OncologyTopic:AMLDate added:07/07/2023Date updated:07/07/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Astellas BioTopic:AMLDate added:07/07/2023Date updated:07/07/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Adicet BioTopic:Cellular TherapyDate added:07/07/2023Date updated:07/07/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerTopic:CMLDate added:07/07/2023Date updated:07/07/2023